Peter Thompson Sells 2,948 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 2,948 shares of the business’s stock in a transaction dated Saturday, April 18th. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96. Following the completion of the transaction, the director directly owned 2,964,774 shares of the company’s stock, valued at $131,991,738.48. The trade was a 0.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Price Performance

NASDAQ:SION traded down $0.85 on Tuesday, reaching $41.79. The stock had a trading volume of 353,348 shares, compared to its average volume of 425,818. Sionna Therapeutics, Inc. has a 12-month low of $10.97 and a 12-month high of $46.46. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -21.43 and a beta of 3.01. The firm’s fifty day moving average is $37.94 and its two-hundred day moving average is $38.63.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.15. As a group, research analysts forecast that Sionna Therapeutics, Inc. will post -2.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sionna Therapeutics

Large investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new position in shares of Sionna Therapeutics in the 4th quarter valued at $36,000. Russell Investments Group Ltd. purchased a new stake in shares of Sionna Therapeutics during the 3rd quarter valued at $30,000. Balyasny Asset Management L.P. acquired a new stake in shares of Sionna Therapeutics during the 4th quarter worth $58,000. BNP Paribas Financial Markets purchased a new position in shares of Sionna Therapeutics in the 2nd quarter worth $31,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Sionna Therapeutics in the 4th quarter worth $89,000.

Wall Street Analyst Weigh In

Several research analysts have weighed in on SION shares. BTIG Research reiterated a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Citizens Jmp initiated coverage on Sionna Therapeutics in a research note on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 target price for the company. Guggenheim increased their target price on Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, UBS Group reissued a “buy” rating on shares of Sionna Therapeutics in a research note on Monday, March 2nd. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.57.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.